Famotidine improved systolic and diastolic function in SHR, reduced cardiac hypertrophy, reduced cardiac fibrosis, reduced histamine concentrations, elevated calcineurin activity, and the phosphorylation of protein kinase B (AKT) in SHR compared with the controls (Potnuri et al., 2018). The gene discussed is AKT1; the disease is cardiac hypertrophy.